Cytokinetics Q2 FY26 net loss widens to $198.76 million; revenue drops to $28.62 million
CYTK•Q2 revenue and net loss
Cytokinetics posted Q2 2026 revenue of $28.62 million, down 57.15% year over year; net loss widened to $198.76 million.
Net product revenue was $25.33 million, including $23 million in the U.S. and $2.3 million in Europe tied to initial Germany distributor inventory.
Expenses, cash and MYQORZO update
Research and development expense fell to $97.81 million; selling, general and administrative expense jumped to $104.4 million, driven by MYQORZO launch costs and higher personnel expense.
Cash, cash equivalents and investments rose to about $1.7 billion at June 30 from $1.1 billion at March 31, following a $760.1 million equity raise.
MYQORZO had 700+ prescribers and about 1,500 patients dispensed as of June 30; the company expects an nHCM supplemental NDA filing in Q4 2026.
